Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced it will release its first-quarter 2022 financial results on May 10, 2022, after market close. A conference call and webcast will be hosted the next morning, May 11, 2022, at 8:30 AM ET, to discuss financial results and provide corporate updates. Catalyst focuses on developing medicines for patients with rare diseases, with its FIRDAPSE® medication approved for Lambert-Eaton myasthenic syndrome. Further details and a replay of the webcast will be available on the company's website.
- Catalyst's FIRDAPSE® medication has been commercially available in the U.S. since 2018.
- FIRDAPSE® is also approved for use in Canada.
- None.
The Company to Host a Conference Call and Webcast on May 11, 2022, at 8:30 AM ET
CORAL GABLES, Fla., April 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will release its first-quarter 2022 financial results after market close on Tuesday, May 10, 2022.
Catalyst's management team will host a conference call and webcast the following morning, Wednesday, May 11, 2022, at 8:30 AM ET, to discuss the Company's financial results and provide a corporate update.
Conference Call & Webcast Details
| Date/Time: | May 11, 2022, at 8:30 AM ET |
| US/Canada Dial-in Number: | (877) 407-8912 |
| International Dial-in Number: | (201) 689-8059 |
A webcast and accompanying materials will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A replay of the webcast will be available on the Catalyst website for 30 days following the date of the event.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2021 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
FAQ
When will Catalyst Pharmaceuticals release Q1 2022 financial results?
What time is the Catalyst Pharmaceuticals conference call?
How can I access the Catalyst Pharmaceuticals conference call?
What is FIRDAPSE® used for?
Where can I find the webcast of the Catalyst Pharmaceuticals conference call?
